Skip to main content
Midas Edge

Shuttle Pharmaceuticals Holdings, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

SHPH$5.59+10.8%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Item 1. Unaudited Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024

Shuttle Pharmaceuticals Holdings, Inc.

Condensed Consolidated Balance Sheets

September 30,December 31,
20252024
Assets
Current assets
Cash and cash equivalents$2,094,643$1,920,144
Prepaid expenses and other current assets1,171,270290,773
Total current assets3,265,9132,210,917
Property and equipment, net18,32719,364
Deferred financing costs30,305—
Operating lease right-of-use asset228,382276,009
Total Assets3,542,9272,506,290
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable and accrued expenses$1,472,897$596,600
Accrued interest payable - related parties—1,785
Notes payable to related parties—190,270
Convertible notes payable, net - fair value option, related parties139,217206,085
Convertible notes payable, net - fair value option278,299478,120
Operating lease liability74,49760,909
Total current liabilities1,964,9101,533,769
Derivative liability8,53825,281
Operating lease liability non-current175,318238,088
Total Liabilities2,148,7661,797,138
Commitments and contingencies (Note 8)-
Stockholders’ Equity
Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 800,000 shares authorized; no shares outstanding——
Common stock, $0.00001 par value; 100,000,000 shares authorized; 1,235,507 shares issued and outstanding at September 30, 2025; 163,093 shares issued and outstanding at December 31, 2024132
Additional paid in capital45,079,02335,287,251
Accumulated deficit(43,684,875)(34,578,101)
Total Stockholders’ Equity1,394,161709,152
Total Liabilities and Stockholders’ Equity$3,542,927$2,506,290

Condensed Consolidated Statements of Operations

Three Months Ended · Nine Months Ended
September 30,September 30,
2025202420252024
Revenue$—$—$—$—
Operating expenses
Research and development943,4781,400,5643,542,9532,632,387
General and administrative886,055328,9953,829,264963,642
Legal and professional437,4091,322,0021,756,3722,323,013
Total operating expenses2,266,9423,051,5619,128,5895,919,042
Net loss from operations(2,266,942)(3,051,561)(9,128,589)(5,919,042)
Other (Expense) income
Interest expense - related parties(721)(2,137)(8,730)(2,137)
Interest expense(18,183)(270,538)(43,847)(1,198,738)
Interest income4862,52456738,135
Change in fair value of derivative liabilities2,427286,31616,743340,405
Change in fair value of convertible notes(64,369)—57,082—
Gain on sale of marketable securities—56,398—100,118
Change in fair value of marketable securities—(42,898)—(71,568)
Loss on settlement of convertible debt—(762,186)—(833,501)
Total other (expense) income(80,360)(732,521)21,815(1,627,286)
Net loss(2,347,302)(3,784,082)(9,106,774)(7,546,328)
Weighted average common shares outstanding - basic and diluted2,233,65095,0041,260,60687,439
Net loss per shares - basic and diluted$(1.05)$(39.83)$(7.22)$(86.30)

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Nine Months September 30, 2025

Additional · Total
Common Stock · Paid-In · Accumulated · Stockholders’
SharesAmountCapitalDeficitEquity
Balance at December 31, 2024163,093$2$35,287,251$(34,578,101)$709,152
Common stock issued for restricted stock units33,609————
Issuance of common stock and pre-funded warrants, net of issuance costs of $693,60053,63715,038,573—5,038,574
Partial conversion of convertible note at fair value5,000—53,500—53,500
Stock-based compensation——537,046—537,046
Net loss———(3,053,007)(3,053,007)
Balance at March 31, 2025255,339340,916,370(37,631,108)3,285,265
Common stock issued for restricted stock units404————
Issuance of common stock and pre-funded warrants, net of issuance costs of $357,98721,924—3,891,964—3,891,964
Partial conversion of convertible note at fair value7,000—68,250—68,250
Exercise of pre-funded warrants786,070819,644—19,652
Common stock issued for reverse stock split fractional share round up36————
Stock-based compensation——46,853—46,853
Net loss———(3,706,465)(3,706,465)
Balance at June 30, 20251,070,7731144,943,081(41,337,573)3,605,519
Common stock issued for restricted stock units14,734————
Exercise of pre-funded warrants150,0002148—150
Reversal of accrued issuance costs related to June 2025 Offering——1,476—1,476
Stock-based compensation——134,318—134,318
Net loss———(2,347,302)(2,347,302)
Balance at September 30, 20251,235,507$13$45,079,023$(43,684,875)$1,394,161

For the Nine Months September 30, 2024

Additional · Total
Common Stock · Paid-In · Accumulated · Stockholders’
SharesAmountCapitalDeficitEquity
Balance at December 31, 202380,348$129,489,074(25,433,304)4,055,771
Common stock issued for conversion of accrued interest and principal3,128—325,298—325,298
Common stock issued for restricted stock units625————
Stock-based compensation——111,449—111,449
Net loss———(1,731,031)(1,731,031)
Balance at March 31, 202484,101129,925,821(27,164,335)2,761,487
Common stock issued for restricted stock units149————
Stock-based compensation——71,162—71,162
Net loss———(2,031,215)(2,031,215)
Balance at June 30, 202484,250129,996,983(29,195,550)801,434
Common stock issued for conversion of convertible debt accrued interest and principal28,766—1,621,996—1,621,996
Common stock issued for restricted stock units201————
Common stock issued for reverse stock split fractional share round up4,629————
Stock-based compensation——45,275—45,275
Net loss———(3,784,082)(3,784,082)
Balance at September 30, 2024117,846$1$31,664,254$(32,979,632)$(1,315,377)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.